Stockwinners Market Radar for March 07, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EST Kidpik Corp trading halted, news pending

18:52 EST Robinhood CEO Tenev sells 250,000 class A shares - In a regulatory filing, Robinhood CEO Vladimir Tenev disclosed the sale of 250,000 class A common shares of the company on March 4 at a price of $16.7614 per share.

17:50 EST Dan McClory acquires majority stake in Brera Holdings - Brera Holdings announced that its Executive Chairman, Daniel J. McClory, an experienced figure in the investment banking world, has acquired a majority stake in Brera Holdings, the first publicly-traded multi-club ownership company in global football. "I believe that this strategic move underscores the robust confidence Mr. McClory places in Brera's potential and heralds in a new era of international focus and expansion beyond the Company's Italian roots," stated Pierre Galoppi, Brera's Chief Executive Officer. Daniel J. McClory is an international investor, investment banker and venture philanthropist, who brings unparalleled expertise, vision, and commitment to Brera, as evidenced by this recent acquisition of 4,550,000 Class A Ordinary Shares, for a total holding of 6,850,000 Class A Ordinary Shares, cementing a 54.5% ownership position and securities entitling him to 83.7% of the total votes of the Company.

17:47 EST Amazon CEO Jassy sells 50,000 common shares - In a regulatory filing, Amazon president and CEO Andrew Jassy disclosed the sale of 50,000 common shares of the company on March 4 at a price of $180 per share.

17:30 EST Nayax to acquire VMtecnologia - Nayax announced a definitive agreement to acquire VMtecnologia, a technology provider for the automated self-service industry in Brazil. VMtecnologia's footprint includes over 2,400 retailers in diverse industries across all 27 states in Brazil and more than 466 cities. The purchase price, equating to an enterprise value of approximately $22.3M, will be paid partially upfront in cash of $13.4M, with $8.9M to be settled semi-annually over the next three years in cash or equity, contingent upon management retention and achieving certain revenue growth over a three-year period. In addition, there is an earnout of up to $5.6M payable primarily in stock based on the achievement of significant three-year growth objectives, bringing the total potential consideration to $27.8M. The transaction is slated for completion in Q2. VMtecnologia's financial performance includes $8.5M in revenue, a gross margin of 88%, and an EBITDA margin exceeding 30%, with a CAGR of approximately 73% between 2021 and 2023. Nayax intends to fund the initial payment with available cash reserves.

17:20 EST Chord Energy announces updates to executive leadership team - Chord Energy announced that Michael Lou will serve as executive VP, chief strategy officer and chief commercial officer and Shannon Kinney will serve as executive VP, chief administrative officer, and general counsel. Additionally, Richard Robuck has been promoted to executive VP and CFO.

16:55 EST American Express board approves boosting quarterly dividend 17% - The board of American Express Company approved a 10c - or 17% - increase in the quarterly dividend on the company's common stock, consistent with the planned increase discussed in the company's Q4 earnings release. The dividend was raised to 70c per common share, from 60c, payable on May 10 to shareholders of record on April 5.

16:43 EST Miller Industries raises quarterly dividend 5.6% to 19c per share - The dividend will be payable March 25, 2024, to shareholders of record at the close of business on March 18, 2024.

16:42 EST QuidelOrtho receives Health Canada Approval for Quidel Triage PLGF Test - QuidelOrtho Corporation has received approval from Health Canada for its Triage PLGF test for laboratory use in Canada. The Triage PLGF test is a fluorescence immunoassay to be used with the small footprint Triage MeterPro Instrument for the quantitative determination of placental growth factor in maternal plasma specimens. The test is intended to detect the presence of angiogenic imbalance, a consequence of abnormal placentation and poor blood flow in the placenta, which can lead to maternal and fetal complications of pregnancy, including pre-eclampsia. Pre-eclampsia is a serious disorder that affects up to 5 percent of pregnancies in Canada. The Triage PLGF test is used with other clinical information to aid in the diagnosis of preterm pre-eclampsia and in the prognosis of short-term delivery in women presenting with signs and symptoms of pre-eclampsia after 20 weeks and prior to 35 weeks of gestation. Diagnosis of pre-eclampsia indicates delivery within 14 days. "When signs or symptoms of pre-eclampsia are present, it is critical to the health and safety of the mother and her unborn baby that clinicians have the information necessary to determine the optimal course of action to achieve the best possible outcome for the pregnancy," said Bernard Michaud, Country Director, Canada at QuidelOrtho. "The Triage PLGF test is intended to help clinicians diagnose pre-eclampsia sooner and may provide them with information on whether the pregnancy is likely to deteriorate within the next 14 days, allowing for a better patient care management plan."

16:37 EST Victoria's Secret announces $250M share repurchase program - The company announced that its board of directors approved a new share repurchase program authorizing the repurchase of up to $250M of the company's common stock. The March share repurchase program replaces the board-authorized January 2023 share repurchase program, which expired at the end of fiscal year 2023.

16:32 EST Gilead says Biktarvy demonstrates high rates of viral suppression - Gilead Sciences announced new data from three studies evaluating the efficacy and safety profile of Biktarvy for a broad range of people with HIV, including those with HIV/hepatitis B coinfection and HIV/tuberculosis coinfection. These data and other studies supporting the important role of Biktarvy in the HIV treatment landscape were presented at the 31st Conference on Retroviruses and Opportunistic Infections. "People with HIV and comorbid conditions or pre-existing treatment resistance can often face complex and evolving treatment needs. These studies were conducted to help bridge the unmet HIV treatment gap and better understand the potential of Biktarvy in a broad range of people and communities affected by HIV and their diverse health needs, said Jared Baeten, MD, PhD, Vice President, HIV Clinical Development, Gilead Sciences. "The data presented at CROI contribute to the growing body of long-term evidence for Biktarvy and reinforce Gilead's commitment to a person-centric approach to HIV treatment research."

16:31 EST ADT authorizes repurchase of 15M shares of its common stock as part of offering - ADT has authorized the concurrent purchase from the underwriters of 15M shares of common stock as part of the secondary public offering subject to the completion of the common stock offering. The share repurchase is part of the company's existing $350M share repurchase program. The underwriters will not receive any underwriting fees for the shares being repurchased by the company.

16:17 EST Alamo Group CFO Richard Wehrle to retire, Agnes Kamps to succeed - Alamo Group announced that Richard Wehrle, Executive Vice President, CFO and Treasurer, will retire from the company on May 3. Agnes Kamps joined the company as Executive Vice-President on March 6, and will take on the duties of company Treasurer immediately. Upon Wehrle's retirement, Kamps will succeed Wehrle as the company's CFO. Kamps joins the company from Americas Styrenics, LLC, where she has served as Vice President and CFO since January 2021.

16:16 EST Express trading halted, news pending

16:12 EST Core Scientific to provide CoreWeave up to 16 MW of data center infrastructure - Core Scientific and CoreWeave announced a multi-year contract for Core Scientific to supply up to 16 MW of data center infrastructure to CoreWeave. The total potential revenue associated with the contract is more than $100M. Under the terms of the contract, Core Scientific will deliver up to 16 MW of capacity at its new Austin, TX data center to host CoreWeave's infrastructure. Core Scientific is leasing a tier 3 data center in Austin that formerly housed Hewlett Packard to expand its hosting business to include HPC. "CoreWeave delivers massive scale GPU compute resources on top of the industry's fastest and most flexible infrastructure," said Michael Intrator, CoreWeave CEO. "Our strong business relationship with Core Scientific is based on years of demonstrated responsiveness, high uptime data centers, professionalism and trust. Both companies share a core belief in accelerating innovation, which our collaboration will help to achieve in rapidly growing applications in AI and high-performance computing."

16:10 EST CBIZ acquires CompuData - CBIZ has acquired technology solutions provider CompuData of Philadelphia, PA, effective March 1. Founded in 1971, CompuData is a technology solutions provider for small and midsize organizations. They provide cloud computing, accounting ERP software, managed IT and security to clients with the tools to scale, protect, and streamline their organizations. CompuData is a Sage Diamond Partner and has Microsoft Partner designation in both Azure Cloud and Modern Work. The firm has 60 employees and approximately $20M in annual revenue.

16:08 EST Inovio expects cash runway to extend into 2H25 - Inovio estimates its cash runway to extend into the second quarter of 2025. This projection includes an operational net cash burn estimate of approximately $26M for the first quarter of 2024. This amount excludes the repayment of $17M in remaining principal and accrued interest on convertible senior notes that matured on March 1, 2024. Including the repayment, the total net cash burn for the first quarter of 2024 is expected to be approximately $43M. These cash runway projections do not include any funds that may be raised through the company's existing at-the-market program or other capital-raising activities.

15:42 EST Infobird Co Ltd trading resumes

15:37 EST Infobird Co Ltd trading halted, volatility trading pause

15:00 EST New York Community Bancorp reverses, down 4% - Shares of New York Community Bancorp, which had initially jumped after resuming trading, have reversed and are now down 14c, or 4%, to $3.09 near 3 pm ET.

14:54 EST GoDaddy sees 6%-8% annual revenue growth between 2024-2026 - Ahead of its investor day, GoDaddy said the event will feature presentations, technology demonstrations and commentary from senior leaders on innovations for customers, as well as its plans for profitable growth and operational excellence. GoDaddy will provide new three-year financial targets to help investors and analysts model its business. The company expects 6% to 8% annual revenue growth between 2024 to 2026, fueled by acceleration in its Applications & Commerce segment; approximately 33% full-year normalized EBITDA margin in 2026; and $4.5B or more in three-year cumulative free cash flow through 2026, with a capital return strategy targeting a free cash flow per share compounded annual growth rate of 20% plus through 2026. GoDaddy says it is committed to continuing to return capital to shareholders. With $1.4B remaining under current share authorizations, the company plans to continue its share buyback program.

14:41 EST GoDaddy trading halted, news pending

14:14 EST New York Community Bancorp names Joseph Otting CEO - New York Community Bancorp announced that Joseph Otting, former Comptroller of the Currency, will become Chief Executive Officer and Sandro DiNello will be named as Non-Executive Chairman, providing his strong banking knowledge in support of Mr. Otting and the Board. Otting also served as CEO of OneWest Bank from 2010 to 2015 and as Acting Director of the Federal Housing Finance Agency in 2018.

14:00 EST Carbon Revolution PLC trading resumes

13:55 EST Carbon Revolution PLC trading halted, volatility trading pause

13:22 EST Ambrx Biopharma shareholders approve acquisition by Johnson & Johnson - Ambrx Biopharma (AMAM) announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson (JNJ) at its Special Meeting of Shareholders. As previously announced, under the terms of the transaction, Ambrx shareholders will receive $28.00 per share in cash in connection with the closing of the transaction. More than 99% of the votes cast at the Special Meeting were voted in favor of adopting the Merger Agreement. Ambrx will disclose the final vote results, as certified by the independent inspector of elections, on a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission. Ambrx now expects to complete the transaction on or about March 7, 2024, subject to the satisfaction of customary closing conditions.

13:00 EST PayPal names Amy Bonitatibus chief corporate affairs, communications officer - PayPal Holdings announcedthat Amy Bonitatibus has been named Chief Corporate Affairs and Communications Officer, effective May 28, 2024. Bonitatibus will report to Diego Scotti, Executive Vice President, Consumer Group & Global Marketing and Communications. Bonitatibus will be responsible for leading the Global Communications team and social impact and sustainability efforts across PayPal's family of brands, including Venmo.

12:40 EST New York Community halts for news pending with shares down 42% to $1.86

12:17 EST New York Community resumes trading, shares down 32% to $2.18

12:11 EST ViiV Healthcare announces interim data of LATITUDE phase III trial - ViiV Healthcare announced data from a planned interim analysis of the LATITUDE phase III trial, indicating that their long-acting injectable antiretroviral treatment for HIV, Cabenuva, demonstrated superior efficacy in maintaining viral load suppression compared to daily oral therapy in individuals with a history of ART adherence challenges. The data were presented by the Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections network at the Conference on Retroviruses and Opportunistic Infections, in Denver, Colorado. LATITUDE is a phase III, randomised, open-label study. Participants received comprehensive and incentivised adherence support while taking guideline-recommended, three-drug regimen oral ART, including dolutegravir and bictegravir-based regimens, to achieve viral suppression. Those who achieved viral suppression were eligible to randomise to staying on oral standard of care regimens or switch to long-acting injectable cabotegravir + rilpivirine dosed monthly. During the randomised phase of the study, 146 participants received monthly LA-ART and 148 continued on SOC. The primary endpoint was a comparison of regimen failure, defined as a combination of virologic failures and regimen discontinuations, between arms. 24.1% of participants on LA-ART experienced regimen failure compared to 38.5% on SOC. Although the primary endpoint did not meet the strict predefined stopping criterion for the interim analysis, key secondary endpoints of virologic failure favoured the LA-ART regimen. The study's Data Safety Monitoring Board considered the totality of all the study endpoints together and concluded that the evidence indicated superior efficacy of long-acting ART over daily oral standard of care. The DSMB recommended that all eligible participants should be offered long-acting injectable cabotegravir + rilpivirine. The rate of adverse events was similar in both arms. Three participants in the LA-ART arm had serious injection site reactions and one participant discontinued due to an ISR. Two confirmed virologic failures in each arm had new resistance associated mutations, including at least two new integrase inhibitor RAMs in both LA-ART participants. The LATITUDE study is ongoing across 31 sites in the U.S. including Puerto Rico, implemented through ACTG. The median age of study participants was 40 years old; 40 percent of participants were male, 64 percent were Black/African American, 17 percent were Hispanic, 5 percent were transgender, and 14 percent currently or previously used injection drugs. The study is sponsored and funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and is being conducted by ACTG, with additional support from the National Institute of Mental Health, the National Institute on Drug Abuse, ViiV Healthcare and the Janssen Pharmaceutical Companies of Johnson & Johnson.

12:04 EST Epic Games says Apple terminated its developer account - "Fortnite" maker Epic Games said that, to the company's suprise, Apple (AAPL) terminated the company's developer account, and that Epic cannot devleop the Epic Games Store for iOS. "We recently announced that Apple approved our Epic Games Sweden AB developer account," Epic Games said. "We intended to use that account to bring the Epic Games Store and Fortnite to iOS devices in Europe thanks to the Digital Markets Act (DMA). To our surprise, Apple has terminated that account and now we cannot develop the Epic Games Store for iOS. This is a serious violation of the DMA and shows Apple has no intention of allowing true competition on iOS devices... In terminating Epic's developer account, Apple is taking out one of the largest potential competitors to the Apple App Store. They are undermining our ability to be a viable competitor and they are showing other developers what happens when you try to compete with Apple or are critical of their unfair practices. If Apple maintains its power to kick a third party marketplace off iOS at its sole discretion, no reasonable developer would be willing to utilize a third party app store, because they could be permanently separated from their audience at any time." Investors in Epic Games include Tencent (TCEHY), KKR (KKR), Disney (DIS), and Sony (SONY). Reference Link

12:00 EST Sonida Senior Living rises 11.6% - Sonida Senior Living is up 11.6%, or $1.72 to $16.53.

12:00 EST Hippo rises 19.8% - Hippo is up 19.8%, or $2.86 to $17.32.

12:00 EST Nordstrom falls -13.8% - Nordstrom is down -13.8%, or -$2.88 to $18.02.

11:59 EST Seagate CFO says company has 'confidence' in midpoint of Q3 guidance - At the Morgan Stanley Technology, Media & Telecom Conference, Seagate CFO Gianluca Romano said that Q3 is coming out as the company expected, and that the company has "confidence" in the midpoint of its guidance. Romano added that the guidance implies a good improvement in its gross margin sequentailly from the previous quarter. In January, the company guided for Q3 earnings per share of 5c-45c on revenue of $1.5B-$1.8B. Wall Street currently expects Seagate to report Q3 EPS of 27c on revenue of $1.67B.

11:50 EST Newmark, BitOoda enter partnership for data center, digital infrastructure - BitOoda has entered into a strategic partnership with Newmark that will allow the firms to combine their expertise and relationships across the AI, data center, and bitcoin mining industries. The partnership will enable BitOoda and Newmark to further serve clients expanding into the AI and Accelerated Compute markets, ranging from startups to data center operators/occupiers to established players in the digital asset space.

11:20 EST Mobileye sees being on track to meet EyeQ volume guidance - While speaking at the Morgan Stanley Technology, Media & Telecom Conference, executives from Mobileye stated: "On our Q4 call, we said that we expected Q1 EyeQ volume to be around 3.4 million units and that we would see an increase of at least 100% in Q2 versus Q1 and at that point the vast majority of the excess inventory would be cleared out. Based on our current view, which includes a significant number of customer commitments we've received for Q2, we believe we are on track to meet that outlook in those statements and that we continue to expect volumes to get back to normalized levels in the second half of the year." Shares of Mobileye are up $2.26, or 9%, to $27.22 as the company continues presenting at the conference.

11:07 EST Independence Pet Holdings enters partnership with Synchrony - Independence Pet Holdings and Synchrony announced that IPH has completed the acquisition of Pets Best Insurance Services from Synchrony. Synchrony received a portion of the consideration as an equity investment in IPH and committed to enter into a commercial agreement with IPH, both of which will help expand IPH's activities in the pet industry and enable both Synchrony and IPH to further capitalize on synergies between Synchrony's CareCredit health and wellness credit card and IPH's products in the pet insurance industry. IPH will also appoint two Synchrony executives to its Board of Directors. IPH has completed the acquisition of Pets Best Insurance Services from Synchrony. Through the collaboration, IPH and Synchrony will explore a diverse range of opportunities, joint product development, key technology partnerships, and insight sharing for improved customer experience and optionality across the pet insurance and pet-care financing industries.

11:03 EST Trxade Health Inc trading resumes

10:53 EST Trxade Health Inc trading halted, volatility trading pause

10:41 EST A SPAC I Acquisition Corp trading resumes

10:34 EST Phio Pharmaceuticals announces patent grant by USPTO - Phio Pharmaceuticals announced that the United States Patent and Trademark Office has granted patent application 17/150,614 for two of its INTASYL Compounds, RXI-185 and RXI-231. The compounds treat age-related skin disorders including photo-aging and dermal hyperpigmentation, targeting the down-regulation of the Matrix metalloproteinase-1 and Tyrosinase proteins. Ultraviolet radiation exposure is a known contributor to skin cancer and aging, inducing the hyperactivity of MMP1 which increases collagen breakdown and reduces collagen synthesis. RXI-185 is a potent silencer of MMP1 expression in the skin, interrupting UVR induced collagen breakdown, thereby, improving and/or slowing the progression for skin thickening, elasticity and wrinkles. Various dermal pigmentation conditions including melasma and lentigines are notoriously difficult to treat. RXI-231 has been shown to penetrate the epidermal-dermal junction where tyrosinase-producing melanocytes reside and reduces the levels of tyrosinase in the skin, resulting in detectable reductions of both melanin and pigmentation in nonclinical studies. The Phio patent portfolio now consists of 81 issued patents, 77 of which cover our INTASYL siRNA gene silencing technology. The portfolio includes patents and applications broadly covering both the composition and methods of use of our INTASYL compounds targeting immune checkpoint, cellular differentiation, and metabolism targets for ex vivo cell-based cancer immunotherapies.

10:19 EST SolarMax Technology Inc trading resumes

10:11 EST Solowin Holdings Ltd trading resumes

10:01 EST Solowin Holdings Ltd trading halted, volatility trading pause

10:00 EST Thor Industries falls -13.8% - Thor Industries is down -13.8%, or -$17.44 to $109.15.

10:00 EST Palantir rises 9.8% - Palantir is up 9.8%, or $2.33 to $26.14.

10:00 EST Hippo rises 18.9% - Hippo is up 18.9%, or $2.73 to $17.19.

09:47 EST Box rises 9.5% - Box is up 9.5%, or $2.59 to $29.84.

09:47 EST Hippo rises 20.3% - Hippo is up 20.3%, or $2.94 to $17.40.

09:47 EST Foot Locker falls -16.0% - Foot Locker is down -16.0%, or -$5.49 to $28.82.

09:43 EST J&J unit applies for Darzalex quadruplet therapy in Europe - Janssen-Cilag International, a Johnson & Johnson company, announced the submission of a Type II variation application to the European Medicines Agency. The submission is seeking approval for an indication extension of Darzalex subcutaneous formulation in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

09:40 EST MicroCloud Hologram Inc trading resumes

09:38 EST Day One Biopharmaceuticals trading resumes

09:35 EST Crown Electrokinetics executes agreement with Twin Dolphin Club - Crown Electrokinetics has executed an agreement with the Twin Dolphin Club. Located in Los Cabos, The Twin Dolphin Club is a 1,400-acre resort master plan development. Crown's Fiber Optics division, led by Corey Boaz, will construct slant wells for the desalination plant that provides fresh water from ocean water to the hotel and surrounding planned residential development. The project is expected to start later this spring and conclude in the early fall time frame. The agreement calls for a $1.2 million upfront payment with a total value of $3.5 million and is expected to lead to other projects of a similar nature. This opportunity was generated, and will be managed by, the Company's new President of Construction, Corey Boaz.

09:33 EST Day One Biopharmaceuticals trading halted, volatility trading pause

09:19 EST Tejon Ranch to aggressively pursue commercial/industrial development - In January of 2024, the Company announced that Nestle USA will start construction on its new distribution center at TRCC East. The new multi-story building, which will total more than 700,000 square feet, will be located on the 58-acre parcel of land that was sold to Nestle in November 2022. The Company will continue to aggressively pursue commercial/industrial development, multi-family development, leasing, sales and investment within TRCC and its joint ventures. The Company also will continue to invest in its residential projects, including Mountain Village at Tejon Ranch, Centennial at Tejon Ranch and Grapevine at Tejon Ranch. California is one of the most highly regulated states in which to engage in real estate development and, as such, natural delays, including those resulting from litigation, can be reasonably anticipated. Accordingly, throughout the next few years, the Company expects net income to fluctuate from year-to-year based on the above-mentioned activity, along with commodity prices, production within its farming and mineral resources segments, and the timing of land sales and leasing of land within its industrial developments. Water sales opportunities each year are impacted by the total precipitation and snowpack runoff in Northern California from winter storms along with SWP allocations. The current SWP allocation is at 15% of contract amounts, with the expectation that the allocation may increase. The Company expects its 2024 farming operations to continue to be impacted by higher costs of production, such as fuel costs, fertilizer costs, pest control costs, and labor costs. The Company is anticipating higher almond industry inventory levels, which may have an adverse effect on 2024 selling prices.

09:17 EST Cyclacel Pharmaceuticals receives $2.9M R&D tax credit - Cyclacel Pharmaceuticals received GBP 2.3 million as a research & development tax credit from HMRC, the tax agency of the United Kingdom government. The tax credit is based on R&D costs incurred in the year ended December 31, 2023. The Company expects to receive an additional approximately $0.8 million following confirmation of a change in the rate of tax credit regarding 2023 expenditures.

09:15 EST Inno Holdings announces factory expansion, automation initiative - INNO Holdings announced a significant expansion of its manufacturing operations and a comprehensive enhancement of its automation infrastructure. This initiative represents a strategic move that augments production capacity and heightens efficiency, positioning INNO Holdings to capitalize on significant market opportunities within the burgeoning global construction materials sector. Amidst a landscape where the global market opportunity for light-gauge steel framing, offsite construction, and prefab home manufacturing is estimated at a staggering $270 billion-comprising $33 billion for global light-gauge steel framing, $130 billion for global offsite construction, and $106 billion for global prefab home manufacturing-INNO Holdings' expansion and modernization efforts are designed to address the rising demand within these segments. The expansion will add 3,500 square feet to the Company's existing facility footprint, facilitating the integration of advanced robotic arms and leading-edge automation technologies. This leap forward underscores INNO Holdings' unwavering commitment to spearheading manufacturing innovation, driving quality production, and maintaining competitive agility in the international arena. The automation overhaul is anticipated to achieve a 30% reduction in manual labor, supporting the Company's strategic focus on technology leverage for operational efficiency and its dedication to enhancing employee well-being by transitioning human capital towards more skilled, less hazardous roles. The factory expansion and automation project commenced in February 2024 and is slated for completion by September 2024.

09:11 EST Rail Vision announces commercial installation of its AI-driven Main Line System - Rail Vision has announced the first commercial installation of its AI-driven Main Line Systems in a national railways line, marking a significant milestone in the Company's journey towards revolutionizing railway safety and efficiency. This commercial installation, which was previously announced on February 20, 2024, was a result of a successful evaluation process which led to the purchase of ten Rail Vision Main Line Systems by Israel Railways.

09:08 EST ResMed announces launch of AirFit F40 - ResMed announced the U.S. launch of the AirFit F40, an ultra-compact, full-face mask offering the comfort of smaller masks without sacrificing performance in order to help improve sleep apnea therapy compliance. Finding the right mask with the right fit and comfort can be daunting, especially for individuals requiring high-pressure CPAP treatment. The AirFit F40 addresses this problem by providing the necessary pressure support in a more comfortable, lower-profile full-face mask. The mask is ideal for people who sleep on their side, are claustrophobic, and want the stability and seal of a universal fit mask in a minimalist design. In a ResMed clinical study, 88% of patients rated AirFit F40's mask cushion as soft and comfortable and 100% found AirFit F40 easy to use

09:06 EST Check Point introduces Harmony SaaS solution - Check Point introduced Harmony SaaS, one of the most advanced solutions for safeguarding against SaaS-based threats. Designed to revolutionize Software as a Service security, Harmony SaaS offers exceptional protection by seamlessly integrating into customers' existing infrastructure and providing real-time threat prevention.

09:06 EST LPL Financial: Aero Capital joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisors Brice Lowe CFP, CPWA and Bradley Moser CFP, have joined LPL Financial's broker-dealer, RIA and custodial platforms, aligned with Mariner Advisor Network. They reported having served approximately $150 million in advisory, brokerage and retirement plan assets and join LPL from Stifel Financial. Based in downtown Wichita, the advisors are native Kansans with a deep connection to their community. Moser came from a fifth-generation farming family, and early on, recognized the need to effectively manage finances and build wealth. Lowe, Moser's stepson, chose to follow the same path into the financial services industry, first interning with Moser during college and later as partner in what would become Aero Capital. Together, they specialize in serving affluent families, business owners and private family foundations by providing comprehensive wealth management services such as wealth planning, asset management, tax-advantaged investment strategies, estate planning review services and charitable giving strategies.

09:05 EST Bloom Energy, Shell to study decarbonization solutions - Bloom Energy (BE) is teaming up with Shell (SHEL) to study decarbonization solutions, utilizing Bloom's hydrogen electrolyzer technology. Bloom and Shell will collaborate with the goal of developing replicable, large-scale, solid oxide electrolyzer, or SOEC, systems that would produce hydrogen for potential use at Shell assets.

09:04 EST DISH Media announces collaboration with Philo - DISH Media announced an exclusive partnership with Philo, the television streaming service, marking a transformative moment in the advertising landscape. Through this collaboration, DISH Media expands its addressable footprint, offering advertisers access to Philo's inventory. This partnership marks the first time that advertisers will have an external reach beyond DISH TV and SLING TV inventory through DISH Media buys, tapping into new, incremental audiences.

09:04 EST Instacart announces new retailers using its Storefront - Instacart announced new retailers using Instacart Storefront to power their e-commerce websites, including Canseco's Market, Harps Foods, and Price Chopper. Instacart Storefront is an easy and affordable way for grocers of all sizes to get online and add e-commerce to their websites. Instacart currently powers owned-and-operated e-commerce storefronts for more than 600 retail banners, enabling them to establish and manage their online presence seamlessly.

09:03 EST Gaxos.AI announces a 1-for-12 reverse stock split - Gaxos.ai announced that it will effect a 1-for-12 reverse split of its issued and outstanding common stock effective as of 4:01pm Eastern Time on March 7, 2024. Commencing with the opening of trading on The Nasdaq Capital Market on March 8, 2024, the Company's common stock will trade on a post-split basis under the same trading symbol, "GXAI".

09:03 EST BorgWarner partners with Manufacture 2030 to reduce supply chain emissions - BorgWarner has entered into a strategic partnership with Manufacture 2030, a decarbonization software provider, to effectively measure and reduce its supply chain carbon footprint and support its goal of reducing absolute Scope 3 greenhouse gas emissions 25% by 2030. Through the agreement, BorgWarner will leverage M2030's extensive expertise in CO2 reduction and unique software to encourage its direct material suppliers to increase their emissions reduction efforts. M2030 will work directly with BorgWarner's supply base to gather energy usage data related to the manufacturing of products such as electricity, natural gas and more. That data will then be fed into an interactive dashboard where emissions and energy reduction efforts can be tracked. The tool also provides best practice sharing opportunities for pursuing emissions reduction. By utilizing the tool, BorgWarner will promote collaboration, accountability and engagement across its supply base on emissions reduction.

09:02 EST Safe Bulkers announces the sale of two dry-bulk vessels - Safe Bulkers announced that it has entered into two separate agreements, for the sale of MV Panayiota K, a 2010-built Post-Panamax class dry-bulk vessel, at a gross sale price of $20.45 million and delivery date in April 2024 and of MV Paraskevi 2, a 2011-built, Panamax class, dry-bulk vessel, at a gross sale price of $20.3 million and forward delivery date in July 2024. Dr. Loukas Barmparis, President of the Company commented: "Following recent newbuild orders, in the context of our fleet renewal strategy, we sold these two vessels in an improved second-hand market environment. Our remaining orderbook consists of seven newbuilds."

08:49 EST Li Auto Li Mega electric vehicle equipped with Hesai Technology - Li Auto (LI) recently launched Li MEGA, its first high-voltage battery electric vehicle. The company's high-tech flagship multi-purpose vehicle, or MPV, is equipped with Hesai Technology's (HSAI) ultra-high-definition long-range LiDAR AT128, which allows for a full suite of intelligent driving capabilities. Li Auto's L8 and L7 Pro models will also feature Hesai LiDAR as a standard configuration with an urban Navigation on AutoPilot function that allows drivers to enjoy the comfort and convenience of safe, intelligent driving. This technology greatly improves intelligent driving systems' obstacle detection, enabling vehicles to quickly respond to unpredictable road conditions.

08:47 EST Omniq awarded purchase order from Burger Ranch - OMNIQ Corp. announced Purchase Order has been awarded to OMNIQ by Burger Ranch. This partnership marks a strategic move to enhance customer service and operational efficiency within the fast-food sector through the adoption of OMNIQ's proprietary Fintech solutions. The purchase order encompasses the supply and installation of OMNIQ's innovative Self Ordering Kiosks and Self-Check-Out Kiosks, along with a newly introduced feature that supports cash transactions. This technology is set to streamline the ordering and payment processes, facilitating a smoother and more efficient customer experience across Burger Ranch's network of over 64 restaurants.

08:43 EST Orchestra BioMed announces presentation of results from study on AVIM therapy - Orchestra BioMed announced the presentation of new clinical data from a pressure-volume loop study of atrioventricular interval modulation, AVIM, therapy in pacemaker-indicated patients with uncontrolled hypertension despite the use of antihypertensive medication. "These results showcase the innovative mechanism of action of AVIM therapy, which acts through well-characterized physiologic mechanisms to substantially reduce blood pressure and favorably impact circulatory hemodynamics," commented Professor Kuck. "Well-conducted invasive PV loop studies are a robust way to evaluate the impact of a novel therapy like AVIM on hemodymanics and overall cardiac function. Results from this study in hypertensive pacemaker patients showing significant decreases in systolic blood pressure, intra-cardiac volumes, total peripheral resistance and cardiac workload, without compromising cardiac output or contractility are encouraging and consistent with the therapy's intended effect. It is also important that these favorable effects occur using both traditional pacing lead locations, as well as conduction system lead positions, which are rapidly emerging as the preferred approach for ventricular pacing given potential benefits to patient safety. These results, in addition to the promising results from prior long-term clinical studies, heighten our excitement about the BACKBEAT global pivotal study that is now underway."

08:41 EST MiNK Therapeutics announces preclinical data from MiNK-215 - MiNK Therapeutics announced the presentation of preclinical data from MiNK-215, an IL-15 armored FAP-targeting CAR-iNKT cell therapy, at the upcoming AACR Meeting, to be held April 5 - 10, 2024 in San Diego, CA. MiNK-215 is an investigational IL-15 armored FAP-targeting CAR-iNKT cell therapy being studied in human organoid models as a novel approach for patients with colorectal cancer liver metastases. "Liver metastases, especially in MSS-CRC, have remained a critical challenge in cancer care and represent a setting where novel therapeutic approaches are urgently needed to improve outcomes for patients," said Dr. Marc van Dijk, Chief Scientific Officer at MiNK. "These first-of-a-kind data underscore the unique potential of iNKT cells to overcome the refractory liver microenvironment. We are proud to partner with Agenus on these innovative models to aid the design of clinical studies that can evaluate the synergy of allogeneic iNKT cells and botensilimab/balstilimab to expand benefit for patients."

08:40 EST Chijet Motor's FAW Jilin breaks ground in South America - Chijet Motor Company announced a significant milestone in its global expansion efforts with the export of 100 Senia R7 taxis to Colombia, South America through its majority-owned subsidiary, FAW Jilin Automobile. The total sales price amounts to $785,000. With a focus on sustainable transportation solutions, FAW Jilin aims to enhance its export activities, with projections indicating a notable increase in exports for 2024.

08:38 EST Bridgeline Digital secures two-year hosting, software license renewal - Bridgeline Digital has secured a two-year hosting and software license renewal with a leading global print and marketing franchise, with $36 thousand in annual recurring revenue. This extension solidifies Bridgeline's role in supporting over 200 locations worldwide, with a lifetime value exceeding $1 million in revenue.

08:37 EST Hepion Pharmaceuticals appoints Purcell to board of directors - Hepion Pharmaceuticals announced the appointment of Michael Purcell to the Company's Board of Directors, effective March 5, 2024.

08:35 EST O-I Glass announces CEO Andres Lopez to retire - O-I Glass announced that Andres Lopez will retire as Chief Executive Officer, effective May 15, 2024, following a nearly 40-year career with the Company. The Board has been working with an executive search firm to identify O-I's next CEO as part of the Company's long-term succession planning process. Andres is committed to supporting a seamless transition of responsibilities to his successor.

08:32 EST Cadiz completes financing transaction - Cadiz announced that it has completed a financing transaction that significantly strengthens its financial position and provides the Company with liquidity to accelerate development of its water supply projects in Southern California. The financing includes a new $20M loan to fund operations and capital expenses associated with development of the Company's water supply projects and extends all debt maturities to 2027. The transaction, led by the Company's largest shareholder, Heerema International Group Services, received strong support from the Company's existing lenders and shareholders. With the completion of this transaction, the Company has a solid financial foundation backed by its lead strategic investor with a substantial capital base committed to the long-term growth of the Company. Cadiz owns 45,000 acres of land in the Mojave Desert with 2.5 million acre-feet of water supply, 1 million acre-feet of water storage capacity and more than 200 miles of pipeline assets that stretch across Southern California. In 2022, the Company also acquired ATEC Water Systems, a producer of specialized groundwater filtration systems. The additional $20 million loan provided by Heerema will carry a 7% PIK coupon and be convertible into Cadiz common stock at a price of $5.30 per share.

08:20 EST 374Water, Inc. secures agreement with City of Orlando - 374Water announced the signing of a contract with the City of Orlando, Florida, to deploy an AirSCWO 6 unit as part of a full-scale demonstration at the City of Orlando's Iron Bridge Regional Water Reclamation Facility. This agreement marks another crucial milestone for 374Water as it continues to strengthen partnerships with major municipalities in order to improve waste management practices and environmental conditions within communities. The agreement is highlighted by the deployment of an AirSCWO 6 service unit, which will be integrated into the City of Orlando's Iron Bridge Regional Water Reclamation Facility. The unit is expected to be deployed in the second quarter of 2024, and intends to treat no less than 400 metric tons of sludge monthly during the three-month collaboration.

08:19 EST Fortune Rise Acquisition receives extension to complete business combination - Fortune Rise Acquisition Corporation announced that Water On Demand Inc., a privately-held subsidiary of OriginClear, and owner of its sponsor, Fortune Rise Sponsor, has deposited the required $100,000 into the Company's trust account for the benefit of its valued public stockholders which provides a one-month extension to complete the Company's initial business combination. This additional contribution extends the date by which the Company has to complete its initial business combination for an additional one-month extension from March 5, 2024 to April 5, 2024. The extension is the fifth of the twelve one-month extensions permitted under the Company's governing documents, as amended in October 2023. Such contribution effectively increases the pro rata portion of the funds available in the Company's trust account in the event of the consummation of an initial business combination, liquidation, or other redemption event, by $0.032 per share. The contribution was funded as a non-interest bearing loan that will either be paid upon earlier of consummation of an initial business combination or the Company's liquidation.

08:18 EST Green Dot appoints Melissa Douros as Chief Product Officer - Green Dot (GDOT) announced the appointment of Melissa Douros as Chief Product Officer. Douros will lead Green Dot's product design and development team with a focus on building simple, seamless and useful tools for Green Dot's customers and growing list of world-class banking-as-a-service BaaS and embedded finance partners. "Melissa is a visionary product leader with deep experience in digital transformation strategy that will be instrumental in driving Green Dot forward as we continue building our platform to best serve the financial needs of businesses and consumers," said George Gresham, Chief Executive Officer, Green Dot Corporation. "Our team will benefit greatly from her ability to translate our product vision and strategy into meaningful solutions for our partners and customers." Prior to joining Green Dot, Douros was vice president of digital experience at Discover Financial Services (DFS), where she led an enterprise-wide digital transformation for the company during a period of rapid business growth. Prior to Discover, Douros also held senior digital product roles at Great Wolf Resorts, Inc. and E*TRADE.

08:15 EST Iterum Therapeutics expects to resubmit oral sulopenem NDA in 1H of 2Q24 - Iterum Therapeutics provided a general business update. Iterum announced that it now expects to resubmit its new drug application for oral sulopenem to the U.S. Food and Drug Administration in the first half of the second quarter of 2024, earlier than originally planned. Provided that the resubmitted NDA addresses all of the deficiencies identified in the complete response letter Iterum received from the FDA in July 2021, Iterum expects that the FDA will complete its review and take action six months from the date the FDA receives the resubmitted NDA. Based on Iterum's current operating plan, Iterum believes that its existing cash and cash equivalents and short-term investments as of December 31, 2023, together with the net proceeds from the sale of ordinary shares under its "at-the-market" offering agreement through February 29, 2024, are expected to enable it to fund its operating expenses into 2025, including through the expected Prescription Drug User Fee Act date in the first half of the fourth quarter of 2024. In January 2024, Iterum announced positive top-line results from the REASSURE trial and that it would be focusing on a strategic process to sell, license, or otherwise dispose of its rights to sulopenem with the goal of maximizing value for its stakeholders. Iterum plans to engage a financial advisor in the near-term to assist management and the Board in evaluating Iterum's strategic alternatives.

08:12 EST Trxade Health announces special cash dividend of $8 per share - TRxADE HEALTH announced that the Company's board of directors has declared a special cash dividend of $8.00 per share of common stock. The special dividend is being paid using a portion of the proceeds from the closing of the recently announced sale of the Company's web-based market platform assets. The special cash dividend is payable to stockholders of record as of March 18, 2024, with the dividend being paid on or about March 22, 2024.

08:10 EST Infinera announces availability of multi-haul OLS functionality for GX Series - Infinera announced commercial availability of next generation multi-haul optical line system functionality on the GX Series compact modular networking platform, the industry's most flexible optical transport solution. Designed for both web-scale operators and communications service providers, the enhanced GX platform provides the lowest cost and power per bit solution and the greatest agility for network operators. Infinera also announced today that it has secured initial design wins for its GX OLS solution from leading CSP and web-scale operator customers, with strong interest across its global customer base.

08:09 EST Aerovate Therapeutics appoints Dable as board of directors - Aerovate Therapeutics announced that its Board of Directors has elected current Board member, Habib Dable, as Chair of the Board. Dable succeeds Mark Iwicki, who will continue to serve on the Board.

08:08 EST International Money Express, PickTrace announces partnership - Intermex announces its partnership with PickTrace, a labor management platform purpose built for large scale farming operations, aimed at facilitating money transfers for workers in US. Marcelo Theodoro, Chief Product, Marketing & Digital Officer at Intermex, stated, "Our paramount goal is always to cater to the needs of our consumers. This partnership merges Intermex's expertise in the remittance industry with PickTrace's robust labor management tools." He further expressed optimism about expanding their digital offerings through this collaboration, providing greater user experience and simplicity to workers in the US. Theodoro emphasized the vital role of cross-border remittances, noting that enabling money transfers in partnership with PickTrace is a significant stride towards promoting financial inclusion across Latin America and diversification of Intermex business.

08:07 EST Equitable Holdings names Julia Zhang as Chief Risk Officer - Equitable Holdings announced new leadership appointments. Julia Zhang has been named the company's Chief Risk Officer, effective April 1, pending approval from the Equitable Holdings Board of Directors. Zhang will report to Mark Pearson, President and Chief Executive Officer of Equitable Holdings, and join the company's Management Committee. Zhang succeeds Aaron Sarfatti, who served as the company's Chief Risk Officer since 2018. "After an extensive search, there is no one better positioned than Julia to lead our enterprise risk management function and build upon our strong framework as we deliver on our growth strategy," said Mark Pearson. "For nearly two decades, Julia has demonstrated impeccable judgment, courage and vision, amidst many market cycles and significant milestones including our IPO in 2018. She is the right leader to guide us into the future, protecting our balance sheet while we drive growth."

08:06 EST Adlucent unveils BEACON application on Google Cloud Marketplace - Adlucent announces the launch of its BEACON application on Google Cloud Marketplace. BEACON enables digital marketers to bring together their first-party data with their data stored in BigQuery, and provides another means to easily implement Google's enhanced conversions via the Google Ads API, offering optimal flexibility and control over advertiser data. With BEACON, advertisers can benefit from privacy-focused data controls over their first-party data and inform marketing and advertising campaigns with more complete data, helping companies achieve above-and-beyond results for their digital marketing campaigns and maximize revenue potential.

08:04 EST LuxUrban Hotels names Robert Arigo as COO - LuxUrban Hotels announced that it has named hotel and hospitality industry veteran Robert Arigo as its COO, effective March 15. Arigo, who brings 35 years of industry experience to LuxUrban, will be primarily responsible for the day-to-day operations of the company's hotel portfolio, with a focus on enhancing property-level operations, optimizing supply chain relationships, elevating the customer experience, and pursuing ancillary revenue opportunities across the company's portfolio. Arigo will be augmenting the company's operations team to support him in this new role.

08:04 EST Arch Resources announces retirement of 315,721 shares - Arch Resources announced that it had retired 315,721 of its outstanding shares via the unwinding of capped calls associated with its now-retired convertible senior notes. With the completion of the cashless transaction, Arch's diluted share count declined from 18.9M shares to 18.6M shares outstanding. These transactions will not result in any changes to Arch's financial position or any impact on its first quarter financial results.

08:02 EST Cognizant and Microsoft announce collaboration - Cognizant (CTSH) and Microsoft (MSFT) are collaborating to infuse generative AI into healthcare administration. This new, groundbreaking collaboration aims to increase productivity and efficiency for healthcare payers and providers, while ensuring timely responses and improved care for patients. The TriZetto Assistant on Facets will leverage Azure OpenAI Service and Semantic Kernel to provide access to generative AI within the TriZetto user interface. Cognizant's TriZetto software platform, powered by Microsoft Azure, is a critical tool that can help healthcare payer and provider clients reduce hidden costs and enable better patient outcomes for millions of Americans.

07:46 EST Ur-Energy files updated S-K 1300 reports for the Lost Creek, Shirley Basin - Ur-Energy has filed updated S-K 1300 Technical Report Summaries for its Lost Creek Property and Shirley Basin Project. The reports are filed as exhibits to the Company's Annual Report on Form 10-K, filed March 6, 2024. Both reports were prepared by Qualified Person, Western Water Consultants, Inc., d/b/a WWC Engineering. Steve Hatten, Ur-Energy COO, "We are very pleased to provide updated Technical Report Summaries related to our producing Lost Creek Property and our Shirley Basin Project. WWC's review of the geologic and economic data supports the continuing potential viability of both projects. While economic conditions have changed in the last two years, both continue to provide excellent potential returns. The Lost Creek Report supports our decision in 2022 to bring the project back into production. Moreover, we have already begun shipping uranium from the newest Lost Creek production areas. The Shirley Basin Report reinforces our belief that Shirley Basin will likely be our second operating project. To that end, we have continued with detailed engineering and production designs while waiting for that production opportunity. With these two properties, Ur-Energy will be ready to supply fuel for clean energy solutions to America's power needs."

07:43 EST Shyft Group selected to join Ford Pro Upfitter program - The Shyft Group was selected to join the Ford Pro Upfitter program, created to provide a seamless end-to-end experience for mutual customers. This designation underscores Shyft's coast-to-coast footprint and reinforces the importance of the collective expertise of Shyft's diverse brand portfolio, promoting cross-brand synergies that drive specialized, customer-focused solutions. Announced at NTEA Work Truck Week, the Ford Pro Upfitter program builds on the successes of Ford's Qualified Vehicle Modifier accreditation program and now encompasses a wider variety of upfit vocations, including shuttle buses, motorhomes, police vehicles and more. Upfitters undergo a rigorous auditing process, demonstrating excellence in compliance, quality, manufacturing and customer service, and must meet specified business and volume requirements set by Ford. In return, Preferred Upfitters are permitted to purchase an unlimited number of chassis from Ford - eliminating the manufacturer's previous cap - and leverage Ford's marketing power and Pro Dealer network to spur growth.

07:41 EST Nexxen sees 2024 adjusted EBITDA of $100M - Management believes ongoing macroeconomic headwinds and uncertainty may continue to limit near-term budgets and spending for some of the Company's largest small- and mid-sized agency customers, drive continued managed service softness, and cause customers to continue to focus spending on lower-cost solutions within Nexxen's broad suite of offerings, but is cautiously optimistic these customers will revert to the Company's premium solutions amidst anticipated improvement in macroeconomic and advertising demand conditions. Management also believes the Company is well-placed to capitalize on industry growth trends following the completed integration of Amobee given its unique positioning to flexibly serve customers on both sides of the ecosystem across formats and devices, expand its end-to-end customer base, increase its base of customers leveraging multiple enterprise tech and data solutions, grow its data licensing revenue, and increase its agency and TV partnerships. Management also anticipates Adjusted EBITDA Margin expansion and CTV revenue growth in full year 2024 compared to full year 2023, and Nexxen provides the following financial guidance: Full year 2024 Contribution ex-TAC in a range of approximately $340 - $345 million; Full year 2024 Adjusted EBITDA of approximately $100 million; Full year 2024 Programmatic revenue to reflect approximately 90% of full year 2024 revenue

07:40 EST Amesite announces launch of active shooter preparedness app - Amesite announces the launch of its mobile safety application, slated for March 31, 2024, to offer Active Shooter Preparedness content developed together with world renowned expert Chris Grollnek. The application will serve Grollnek's expansive audience and customer base, including Fortune 100 and 500 companies, small to large corporations and businesses, the entire government sector, public entities, and other organizations. This broad client base reflects the universal need for effective crisis response training across all sectors of society. Dr. Ann Marie Sastry, CEO of Amesite, stated, "Global thought leaders like Chris need a platform to deliver online consulting and learning, and Amesite is that home. Our AI-powered platform offers best-in-class infrastructure and learning programs that are quickly and efficiently deployed. We are thrilled to support Chris in helping keep organizations and communities safer, 24/7 and globally."

07:37 EST Evertec enters $70M accelerated share repurchase agreement - Evertec announced that it has entered into an accelerated share repurchase, or ASR, agreement with Bank of America by which the company will repurchase $70M of its common stock. The ASR is expected to be completed by the third quarter. Additionally, the company's board of directors approved an increase to the share repurchase authorization to an aggregate $220M and an extension to the expiration date to December 31, 2025. The ASR was executed under this increase. Prior to this amendment, the share repurchase program had approximately $137M remaining. The company may repurchase shares in the open market, through accelerated share repurchase programs, 10b5-1 plans, or in privately negotiated transactions, subject to business opportunities and other factors.

07:36 EST 23andMe launches new genetic report on forms of cancer - 23andMe Holding released three new genetic reports for 23andMe+ members on breast, colorectal and prostate cancer. The reports are based on statistical models known as polygenic risk scores, developed by 23andMe through its proprietary research database. These PRS reports calculate the likelihood of an individual developing one of these cancers, based on thousands of genetic variants associated with the disease. "Using these reports to understand your likelihood to develop common cancers is an important step toward further integrating genetics into healthcare," said Noura Abul-Husn, Vice President of Genomic Health at 23andMe. "Today, there is increasing evidence and support for the use of PRS in personalized disease prevention, and certain medical specialties - including oncology - have already begun to adopt this to inform clinical decision-making. These new reports will help customers better understand their overall likelihood for developing these diseases, and enable them to work with their healthcare providers to implement prevention plans."

07:35 EST BiomX enters merger agreement with Adaptive Phage Therapeutics - BiomX announced that it has entered into a definitive merger agreement with Adaptive Phage Therapeutics, a U.S.-based privately-held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections. Immediately after the effective time of the Acquisition, and before giving effect to the concurrent private placement the former stockholders of BiomX will own approximately 55% and the former stockholders of APT will own approximately 45% of the consolidated entity of BiomX and APT. The Acquisition is expected to close within the next 30 days, subject to the satisfaction of the closing conditions described in the definitive merger agreement. Concurrently with entering into the definitive merger agreement, BiomX entered into a definitive purchase agreement for the sale of shares of newly created non-voting convertible preferred stock and warrants to purchase shares of BiomX common stock in a private placement to certain institutional accredited investors led by affiliates of Deerfield Management Company and the AMR Action Fund, and additional investors including the Cystic Fibrosis Foundation, OrbiMed and Nantahala Capital. The private placement is expected to result in gross proceeds to BiomX of $50 million before deducting placement agent and other offering expenses. The proceeds from the private placement are expected to provide funding through the results from a planned Phase 2b trial that will evaluate BiomX's lead product candidate, BX004, for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa in CF patients expected in the third quarter of 2025 and Phase 2 results from APT's clinical-stage product candidate, now named BX211, for the treatment of Staphylococcus aureus infections in DFO patients expected in the first quarter of 2025. The private placement is expected to close substantially concurrently with, and subject to the closing of, the Acquisition. BiomX will continue to be led by its current management team, with the addition of Michael Billard from APT as General Manager, U.S. Following the transaction, the BiomX board of directors will be comprised of Dr. Russell Greig, Chair of the Board of Directors, and the following members of the board of directors - Dr. Jesse Goodman, Jonathan Leff, Dr. Alan Moses, Greg Merril, Eddie Williams and Jonathan Solomon, BiomX's CEO. The Acquisition is structured as a stock-for-stock transaction whereby all outstanding equity interests of APT will be exchanged in a merger for 9,164,967 shares of BiomX common stock, 40,471 shares of Series X Preferred Stock convertible into 40,471,000 shares of BiomX common stock and warrants exercisable for 2,166,497 shares of BiomX common stock. Following the consummation of the Acquisition, a successor-in-interest of APT will become a wholly-owned subsidiary of BiomX. The Merger Warrants will be exercisable at any time after the date of the receipt of stockholder approval at an exercise price of $5.00 per share and will expire on January 28, 2027. The definitive merger agreement is subject to various closing conditions, including, among other conditions, receiving cash of not less than $50 million from the private placement. Concurrently with the entry into the definitive merger agreement with APT, BiomX entered into a definitive purchase agreement for a private placement investment with existing and new investors to raise $50 million, in which the investors have agreed to purchase an aggregate of 216,417 shares of Series X Preferred Stock and warrants to purchase up to an aggregate of 108,208,500 shares of BiomX common stock, at a combined purchase price of $231.10 per share of Series X Preferred Stock and an accompanying Private Placement Warrant to purchase 500 shares of common stock. The Private Placement Warrants will be exercisable any time after the date of the receipt of BiomX stockholder approval, at an exercise price of $0.2311 per share, and will expire on the 24-month anniversary of the initial exercisability date. The closing of the private placement offering is subject to the satisfaction of customary closing conditions, including but not limited to the consummation of the Acquisition. Subject to BiomX stockholder approval, each share of Series X Preferred Stock issued in the Acquisition and the private placement initially will be convertible into 1,000 shares of BiomX common stock, and subject to certain beneficial ownership limitations set by each holder not to exceed 19.99%. The definitive merger agreement was approved by the Board of Directors of BiomX and the Board of Directors and stockholders of APT. The closing of the Acquisition will not be subject to the approval of BiomX stockholders. In connection with the execution of the definitive merger agreement, certain stockholders of BiomX, together holding on as converted basis over 50% of the outstanding shares of common stock of BiomX, have agreed to vote their shares in favor of the conversion of the Series X Preferred Stock.

07:31 EST Phoenix Motor sells six all-electric transit buses to Raleigh Durham airport - Phoenix Motor announced that repeat customer Raleigh Durham International Airport has placed an order for six zero emission Phoenix battery electric buses, marking Phoenix's first formal order after acquiring the Proterra Transit business line. The six ZX5+ buses were manufactured in Greenville, South Carolina and Phoenix looks forward to continuing its longstanding relationship with RDU to deliver these buses later this month.

07:25 EST Xeris Biopharma refinances senior secured term loan agreement with Hayfin - On March 6 Xeris announced the refinancing of its existing senior secured term loan agreement with Hayfin Capital Management to provide the Company with a facility size of $200M at close, lowering its overall cost of capital and providing additional working capital to invest in the Company's business plan. An additional $15.2 M will be available to settle, if needed, the outstanding senior convertible notes that mature mid-2025. In conjunction with the new loan agreement, Xeris paid the balance of the $15M debt facility to Hayfin, plus associated interest and fees.

07:20 EST Kamada issues letter to shareholders - Kamada issued a Letter to Shareholders from Amir London, Chief Executive Officer. "The recently completed 2023 was another successful period in our commercial journey as a global leader in the specialty plasma-derived field. During the year, we continued our major transformation to a diversified, fully integrated specialty plasma company with six U.S. Food and Drug Administration approved proprietary products and strong commercial capabilities in the U.S. market, as well as a sales footprint in over 30 countries.... Looking ahead, we expect the momentum from 2023 to extend throughout 2024, with profitability to be further increased as compared to last year. As such, we are introducing full-year 2024 revenue guidance of $156 million to $160 million, and adjusted EBITDA guidance of $27 million to $30 million, which would represent double digit top- and bottom-line growth... These significant catalysts are propelling our continued annual double-digit profitable growth with substantial upside potential and limited downside risk. KEDRAB, our anti-rabies immunoglobulin, was especially impactful in 2023 and following the recent amendment and extension of our distribution agreement with Kedrion, we expect this trend to continue in 2024 and beyond... We are confident that the continuation of our partnership with Kedrion maximizes the future growth and value potential of KEDRAB, while it also most effectively exploits our U.S. business... CYTOGAM is the largest of the four products we are self-marketing... In addition to KEDRAB growth and our U.S. promotional activities, we are leveraging our strong international distribution network to expand revenues of our IgG portfolio in other territories, primarily in Canada, Asia, Latin America and the Middle East, as well as with the Pan American Health Organization. We are also very excited about our innovative investigational Inhaled AAT product candidate for the treatment of AAT Deficiency, a technology that has been shown to be highly effective in delivering AAT directly into a patient's lungs... Another major strategic step we are taking is the advancement of our plasma collection business through our wholly owned subsidiary, Kamada Plasma, based in Texas... In our distribution segment, we are leveraging our expertise and strong presence in the Israeli market to register, market and distribute more than 25 products that are developed and manufactured by our international partners... On behalf of the entire Kamada team, we look forward to continuing to support patients and clinicians with the important lifesaving products that we develop, manufacture, and commercialize. We thank all of our investors for their support and remain committed to creating long-term shareholder value."

07:15 EST Tilray's Breckenridge Brewery announces return of Nitro Irish Stout - Breckenridge Brewery announces the return of its Go Gold Sweepstakes with Nitro Irish Stout. "Our Go Gold Sweepstakes is one of the best ways for us to share this deliciously smooth Stout with beer lovers across the country," said Ryan Workman, Director of Marketing at Breckenridge Brewery. "Nitro Irish Stout has become a Breckenridge favorite because it combines the magic and softness of Nitro with the spirit of Colorado."

07:13 EST Ayr Wellness celebrates opening of Tallahassee retail location - AYR Cannabis Dispensary announced the opening of the relocated AYR Cannabis Dispensary Tallahassee. "We always strive to offer our patients the best experience possible, and the relocation of our Tallahassee dispensary is yet another example of doing so," said Sevi Borrelli, SVP, Market General Manager, Florida. "AYR Dispensary Tallahassee provides an inviting and comfortable experience, while offering the high-quality products you love. I can't wait to welcome the patient community of Florida at our new location this spring."

07:12 EST Pluri appoints James Roosevelt, Jr. to advisory board - Pluri announced the appointment of attorney James Roosevelt, Jr. to the Company's Advisory Board. Having served in public-service positions in Washington, D.C., followed by a successful decade in the private sector as CEO of Tufts Health Plan, Roosevelt is a trusted and sought-after advisor.

07:11 EST Aslan Pharmaceuticals announces new data on eblasakimab, appointments - ASLAN Pharmaceuticals announced new positive translational data from a head-to-head study of eblasakimab versus dupilumab in a human tissue model of chronic obstructive pulmonary disease, COPD, that provides further support for the potential of eblasakimab as a biologic therapy for COPD. In addition, the Company announced the appointment of respiratory experts Dr Ramaswamy Krishnan, MS MPhil PhD, Associate Professor in Emergency Medicine, Harvard Medical School, and Dr Reynold Panettieri Jr, MD, Vice Chancellor, Translational Medicine and Science, Rutgers University to ASLAN's Scientific Advisory Board as it evaluates the potential use of eblasakimab as a therapy to treat COPD in addition to atopic dermatitis, AD. "We believe that eblasakimab has the potential to be a leading treatment option as we explore its applicability in other diseases besides AD, such as COPD, a large, underserved market with no approved biologics. We look forward to working with Drs Krishnan and Panettieri, and potential partners, to consider potential proof-of-concept Phase 2 study designs in COPD and exploring novel endpoints from recently conducted biologic studies," said Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals.

07:09 EST Olema Oncology announces publication of data on palazestrant - Olema Pharmaceuticals announced that Molecular Cancer Therapeutics, an American Association for Cancer Research journal, has selected as a featured article a data publication that describes the distinct properties of palazestrant. The paper, titled "Palazestrant, a Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination", describes the scientific background underlying the design, discovery and optimization of palazestrant. "The research described in this paper reviews the deliberate design and processes used in discovering and optimizing palazestrant as a molecule purpose-built to address a crucial unmet need in the treatment of women's cancers, and we are delighted that Molecular Cancer Therapeutics has featured our work," said David C. Myles, Ph.D., Olema's Chief Discovery and Non-Clinical Development Officer. "What's even more exciting is to see how faithfully the pre-clinical research predicted the behavior of palazestrant now that it is in late-stage clinical development. We saw the potential then, as told in the paper, and we believe that every day brings us closer to having a real impact transforming the treatment paradigm for women with cancer."

07:06 EST Dalet and Veritone in deal to distribute, transact and monetize media archives - Dalet and Veritone announced a technology partnership that integrates the Dalet Flex media workflow ecosystem with Veritone's AI-powered Digital Media Hub DMH, featuring its commerce and monetization capabilities. The integration enables a seamless workflow from content creation through production, curation, packaging, and distribution, empowering media, sports, and entertainment customers to monetize their digital media archives...The Dalet and Veritone referral partnership enables media and entertainment companies to maximize the return on investment of their content assets to generate new revenue streams. The secure, scalable, and robust solution enables media-centric organizations to automatically deliver content to partners while remaining in control of their content catalog. "Veritone's AI-enabled technology has long been the tool of choice for some of the world's most recognized brands because of its ability to more efficiently and effectively organize, manage, and monetize content," said Sean King, SVP, GM at Veritone. "Veritone and Dalet share a commitment to unlocking the true potential of digital content and we're pleased to offer the content monetization capabilities of DMH to complete Dalet's end-to-end platform and provide endless revenue opportunities to their customer base."

07:05 EST Berry Corporation sees 2024 average daily production 24,600-25,800 boe/d - Berry's 2024 capital program reflects management's prior experience with the constraints imposed by the current permitting litigation impacting Kern County, with an underlying commitment to maximize Adjusted Free Cash Flow and shareholder value. Our current plan is based on 2024 production that is essentially flat to 2023. Berry's current capital program for 2024 focuses on sidetracks, workovers and other activities related to existing wellbores. The Company expects to benefit from a full year of production from the assets acquired in the Macpherson Acquisition and another bolt-on acquisition completed at the end of 2023, which should help keep our production essentially flat in 2024. As a result of the ongoing regulatory uncertainty in California impacting the permitting process in Kern County where all of our California assets are located, the capital program has been prepared based on the assumption that we will not receive additional new drill permits in California in 2024, but that we will continue to timely receive the other permits and approvals needed for planned activities, in addition to the permits we already have in hand. However, should there be favorable changes to the permitting process we are well prepared to take advantage of the opportunities. In 2024, the Company expects to continue to focus on debt and leverage, including looking at opportunistically refinancing the senior notes due February 2026, if market conditions allow. The Company also expects to reduce general and administrative expenses, as well as operating costs, primarily energy costs which is reflected in the 2024 guidance. The Company has oil hedges for more than 80% of its expected 2024 oil production, while approximately 70% of the expected production is hedged with swaps with an average strike price of $77.97 per barrel Brent. The Company has gas purchase hedges for approximately three quarters of its expected 2024 gas demand, approximately 96% of this position is swaps with an average strike of $3.99 per mmbtu.

07:02 EST Palantir USG awarded $178.4M prime agreement by Army Contracting Command - Palantir Technologies announced that the Army Contracting Command - Aberdeen Proving Ground, or ACC-APG, has awarded Palantir USG, a wholly-owned subsidiary of Palantir Technologies, a prime agreement for the development and delivery of the Tactical Intelligence Targeting Access Node, or TITAN, ground station system, the Army's next-generation deep-sensing capability enabled by artificial intelligence and machine learning, or AI/ML. The agreement, valued at $178.4M, covers the development of 10 TITAN prototypes, including five Advanced and five Basic variants, as well as the integration of new critical technologies and the transition to fielding. TITAN is a ground station that has access to Space, High Altitude, Aerial, and Terrestrial sensors to provide actionable targeting information for enhanced mission command and long range precision fires. This was awarded through an Other Transaction Authority agreement, which allows the Army to leverage innovative solutions from non-traditional defense contractors. This award is a successful progression of the Army's competitive, software-centric approach to the June 2022 competitive prototyping phase of the TITAN Program.

06:53 EST OpenAI says Elon Musk wanted 'full control' of company - In a company blog post, OpenAI said, "The mission of OpenAI is to ensure AGI benefits all of humanity, which means both building safe and beneficial AGI and helping create broadly distributed benefits. We are now sharing what we've learned about achieving our mission, and some facts about our relationship with Elon. We intend to move to dismiss all of Elon's claims...Elon said we should announce an initial $1B funding commitment to OpenAI. In total, the non-profit has raised less than $45M from Elon and more than $90M from other donors. When starting OpenAI in late 2015, Greg and Sam had initially planned to raise $100M. Elon said in an email: 'We need to go with a much bigger number than $100M to avoid sounding hopeless... I think we should say that we are starting with a $1B funding commitment... I will cover whatever anyone else doesn't provide.' We spent a lot of time trying to envision a plausible path to AGI. In early 2017, we came to the realization that building AGI will require vast quantities of compute. We began calculating how much compute an AGI might plausibly require. We all understood we were going to need a lot more capital to succeed at our mission-billions of dollars per year, which was far more than any of us, especially Elon, thought we'd be able to raise as the non-profit...As we discussed a for-profit structure in order to further the mission, Elon wanted us to merge with Tesla or he wanted full control. Elon left OpenAI, saying there needed to be a relevant competitor to Google/DeepMind and that he was going to do it himself. He said he'd be supportive of us finding our own path. In late 2017, we and Elon decided the next step for the mission was to create a for-profit entity. Elon wanted majority equity, initial board control, and to be CEO. In the middle of these discussions, he withheld funding. Reid Hoffman bridged the gap to cover salaries and operations. We couldn't agree to terms on a for-profit with Elon because we felt it was against the mission for any individual to have absolute control over OpenAI. He then suggested instead merging OpenAI into Tesla. In early February 2018, Elon forwarded us an email suggesting that OpenAI should 'attach to Tesla as its cash cow', commenting that it was 'exactly right...Tesla is the only path that could even hope to hold a candle to Google. Even then, the probability of being a counterweight to Google is small. It just isn't zero'. Elon soon chose to leave OpenAI, saying that our probability of success was 0, and that he planned to build an AGI competitor within Tesla. When he left in late February 2018, he told our team he was supportive of us finding our own path to raising billions of dollars. In December 2018, Elon sent us an email saying 'Even raising several hundred million won't be enough. This needs billions per year immediately or forget it.'"

06:42 EST Thor Industries drops 13% to $110.00 after cutting FY24 guidance

06:41 EST Terran Orbital awarded $45M IDIQ contract with NASA - Terran Orbital announced being awarded an Indefinite-Delivery/Indefinite-Quantity, or IDIQ, contract with a $45M ceiling value with NASA's Space Technology Mission Directorate. The Directorate is comprised of NASA's Flight Opportunities program and the Small Spacecraft Technology program. The five-year agreement enables Terran Orbital to provide space vehicles and payload integration services for a variety of missions. These missions will utilize Terran Orbital's space vehicle platforms and are intended to advance technological maturity of systems that will transform the landscape of space exploration, discovery, and space commerce. NASA's selection of Terran Orbital was based on the proven capabilities of the company's standard space vehicle platforms, including the successful and proven Pathfinder-Triumph Class 6U CubeSat and Capstone-Voyager Class 12U CubeSat. These platforms offer the required size, capability, and performance required for these NASA missions.

06:35 EST Waymo launches driverless rides for employees in Austin - Waymo will begin allowing its autonomous vehicles to drive in Austin without a safety operator behind the wheel, according to a tweet by Waymo Chief Product Officer Saswat Panigrahi. "We are excited to begin driving with no human at the wheel in #Austin tomorrow! The @Waymo Driver continues to impress after months of careful testing, and this milestone brings us a step closer to launching in our 4th ride-hail city," he said in a Tuesday tweet. "We'll be driving across 43 square miles of Austin, encompassing the heart of downtown, Barton Hills, Riverside, East Austin, Hyde Park and more." Reference Link

06:25 EST GE Vernova expects to invest $1B annually in R&D - GE Vernova (GEV) is expected to spin off from GE (GE) on April 2, and list on the New York Stock Exchange under the ticker symbol "GEV." On February 29, to effect the separation, GE's Board of Directors approved a distribution to GE shareholders of all shares of GE Vernova's common stock.

06:01 EST IBM opens new IBM X-Force Cyber Range in Washington, DC - IBM announced the official opening of the new IBM X-Force Cyber Range in Washington, DC. The range includes new custom training exercises specifically designed to help U.S. federal agencies, their suppliers and critical infrastructure organizations more effectively respond to persistent and disruptive cyberattacks, and threats posed by AI. The facility is designed to help everyone from legal and mission-critical leaders, to the C-Suite and technical security leaders prepare for a real-world cyber incident.

05:52 EST Infosys renews partnership with ATP Tour until 2026 - Infosys announced the renewal of its digital innovation partnership with the ATP Tour until 2026. The three-year extension of the partnership will continue to draw on Infosys' deep expertise in digital technologies like Artificial Intelligence, Data Analytics, and Cloud, which will enrich the fan experience and player performance in professional tennis.

05:39 EST Innate Pharma announces first patient dosed in IPH6501 trial - Innate Pharma announced the first patient was dosed in its Phase 1/2 multicenter trial, investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma, or NHL.

05:30 EST Calliditas gets additional seven year orphan drug exclusivity period for Tarpeyo - Calliditas Therapeutics announced that the FDA has granted an orphan drug exclusivity period of seven years for Tarpeyo, expiring in December 2030 based on when the company obtained full approval with a new indication for this drug product. Following full approval in December 2023, Tarpeyo is indicated 'to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy who are at risk for disease progression'. The exclusivity period reflects the new indication covering all adult patients with primary IgAN at risk of disease progression based on a confirmed reduction of kidney loss reflecting a clinical benefit on kidney function for adult patients with primary IgAN.

05:24 EST Analog Devices, BMW join forces to provide 10MB ethernet for vehicles - Analog Devices (ADI) and the BMW Group (BMWYY) announced an early adoption of EB, ADI's 10BASE-T1S Ethernet to the Edge bus technology within the automotive industry. Automotive ethernet connectivity is a key enabler of new, zonal architectures in automotive design and supports automotive megatrends such as software-defined vehicles. The BMW Group will be a leading original equipment manufacturer to implement the technology, leveraging ADI's EB for their ambient lighting system design in the vehicles of the BMW Group in the future. Since 2018, ADI has been working closely with the BMW Group on a new concept to simplify bringing Ethernet to the Edge. At the same time, the IEEE802.3cg Group was defining a new 10Mbps Ethernet standard called 10BASE-T1S, with ADI and the BMW Group among other companies both actively involved. Using ADI's 10BASE-T1S EB technology to remove microcontrollers and move software from edge nodes to central processing units, the BMW Group enables an all-hardware edge node while reducing software development and qualification tasks.